Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 07, 2019 06:46pm
By Marcelo C. Pasquini, MD
Susan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.
Susan Prockop, MD, associate attending in pediatrics at Memorial Sloan Kettering Cancer Center, discusses an option available for the treatment of central nervous system (CNS) Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD).
According to a subset analysis, patients are at very high risk of developing this disease after hematopoietic stem cell transplant or solid organ transplant and the modalities available are still limited, Prockop says. A high dose of radiation can be debilitating with significant side effects, so adoptive immunotherapy with EBV-specific T cells is a good option for these patients.